|
|
 |
 |
 |
|
GSK's Tykerb up against Herceptin in early breast cancer study
GlaxoSmithKline has begun another late-stage trial comparing its new oncology agent Tykerb/Tyverb against Roche/Genentech’s blockbuster Herceptin as a treatment for early breast cancer
Read more ...
|
|
 |
|